GLP-1 (7-37) vs Pramlintide

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

The active endogenous form of glucagon-like peptide-1, an incretin hormone released from intestinal L-cells after eating. The mechanistic basis for the GLP-1 receptor agonist drug class (semaglutide, liraglutide). Studied for glucose regulation and appetite suppression.

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

FDA-approved synthetic amylin analogue that complements insulin therapy. Reduces postprandial glucose spikes and suppresses appetite, aiding weight management in T1D and T2D.